[go: up one dir, main page]

WO2001068889A3 - Method for gene transfection and vaccination through skin using electropermeabilization - Google Patents

Method for gene transfection and vaccination through skin using electropermeabilization Download PDF

Info

Publication number
WO2001068889A3
WO2001068889A3 PCT/US2001/008502 US0108502W WO0168889A3 WO 2001068889 A3 WO2001068889 A3 WO 2001068889A3 US 0108502 W US0108502 W US 0108502W WO 0168889 A3 WO0168889 A3 WO 0168889A3
Authority
WO
WIPO (PCT)
Prior art keywords
skin
gene
polynucleotide
approach
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/008502
Other languages
French (fr)
Other versions
WO2001068889A2 (en
Inventor
Robert W Malone
Jill G Malone
Joseph J Drabick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU2001250859A priority Critical patent/AU2001250859A1/en
Publication of WO2001068889A2 publication Critical patent/WO2001068889A2/en
Publication of WO2001068889A3 publication Critical patent/WO2001068889A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/327—Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0412—Specially adapted for transcutaneous electroporation, e.g. including drug reservoirs
    • A61N1/0416—Anode and cathode
    • A61N1/0424—Shape of the electrode
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Cells in the skin or mucosal tissue of an individual can be transfected with a polynucleotide or gene by injecting the polynucleotide into the skin or mucosal tissue and applying a pulsating electrical field in the vicinity of the injection. This approach is suitable for vaccinating an individual to the expressed polypeptide, thereby generating antibodies or to engendering cell-mediated immunity. For example, antibodies generated against the expression product of a gene cloned from genomic or cDNA libraries can be used to characterize the product and, hence, illuminate the function of the gene. The approach also can be employed, in an animal or human, for treating a disease condition or for modifying a skin condition that affects the appearance of the skin. Kits are included for carrying out the methods of the invention.
PCT/US2001/008502 2000-03-16 2001-03-16 Method for gene transfection and vaccination through skin using electropermeabilization Ceased WO2001068889A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001250859A AU2001250859A1 (en) 2000-03-16 2001-03-16 Method for gene transfection and vaccination through skin using electropermeabilization

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18984700A 2000-03-16 2000-03-16
US60/189,847 2000-03-16

Publications (2)

Publication Number Publication Date
WO2001068889A2 WO2001068889A2 (en) 2001-09-20
WO2001068889A3 true WO2001068889A3 (en) 2002-04-25

Family

ID=37488067

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/008502 Ceased WO2001068889A2 (en) 2000-03-16 2001-03-16 Method for gene transfection and vaccination through skin using electropermeabilization

Country Status (2)

Country Link
AU (1) AU2001250859A1 (en)
WO (1) WO2001068889A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2224008A3 (en) 2005-05-12 2010-12-01 Murdoch University Genes and proteins of brachyspira hyodysenteriae and use of same for diagnosis and therapy
US20080033398A1 (en) * 2005-12-29 2008-02-07 Transcutaneous Technologies Inc. Device and method for enhancing immune response by electrical stimulation
JP2010535030A (en) 2007-08-03 2010-11-18 スピロジーン ピーティーワイ エルティーディー Novel genes and proteins of Brachyspira hyodysenteriae and their use
GB0720250D0 (en) 2007-10-17 2007-11-28 Univ Edinburgh Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof
EP2363407A1 (en) 2008-02-28 2011-09-07 Murdoch University Novel sequences of Brachyspira, immunogenic compositions, methods for preparation and use thereof
WO2009117773A1 (en) 2008-03-27 2009-10-01 Murdoch University Novel sequences of brachyspira, immunogenic compositions, methods for preparation and use thereof
ITCO20080016A1 (en) * 2008-04-22 2009-10-23 Giuseppe Caccia HANDPIECE FOR THE ELECTROPORATION OF PHARMACOLOGICAL AND / OR NATURAL AND / OR AESTHETIC PRODUCTS ON LAYERS CUTANEOUS WITH THICKNESS CONTENT

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019034A (en) * 1988-01-21 1991-05-28 Massachusetts Institute Of Technology Control of transport of molecules across tissue using electroporation
WO1991018103A1 (en) * 1990-05-16 1991-11-28 Scientific Equipment Design & Development S.C. Method and device for making living cells permeable
WO1996039531A1 (en) * 1995-06-06 1996-12-12 Massachusetts Institute Of Technology Delivery of nucleotides into organisms by electroporation
WO1997007826A1 (en) * 1995-08-29 1997-03-06 Cbr Laboratories, Inc. In vivo electroporation of cells
WO1999064615A1 (en) * 1998-06-08 1999-12-16 Valentis, Inc. Formulations for electroporation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019034A (en) * 1988-01-21 1991-05-28 Massachusetts Institute Of Technology Control of transport of molecules across tissue using electroporation
US5019034B1 (en) * 1988-01-21 1995-08-15 Massachusetts Inst Technology Control of transport of molecules across tissue using electroporation
WO1991018103A1 (en) * 1990-05-16 1991-11-28 Scientific Equipment Design & Development S.C. Method and device for making living cells permeable
WO1996039531A1 (en) * 1995-06-06 1996-12-12 Massachusetts Institute Of Technology Delivery of nucleotides into organisms by electroporation
WO1997007826A1 (en) * 1995-08-29 1997-03-06 Cbr Laboratories, Inc. In vivo electroporation of cells
WO1999064615A1 (en) * 1998-06-08 1999-12-16 Valentis, Inc. Formulations for electroporation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BANGA A K ET AL: "Assessing the potential of skin electroporation for the delivery of protein- and gene-based drugs", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 16, no. 10, 1 October 1998 (1998-10-01), pages 408 - 412, XP004145647, ISSN: 0167-7799 *
BARON S ET AL: "Electroporation of antibodies, DNA, and other macromolecules into cells: a highly efficient method", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 242, no. 1-2, 28 August 2000 (2000-08-28), pages 115 - 126, XP004210715, ISSN: 0022-1759 *
JOSEPH J. DRABICK ET AL: "Cutaneous Transfection and Immune Responses to Intradermal Nucleic Acid accination Are Significantly Enhanced by in Vivo Electropermeabilization", MOLECULAR THERAPY, vol. 3, no. 2, February 2001 (2001-02-01), pages 249 - 255, XP002190195 *
SELBY M ET AL: "Enhancement of DNA vaccine potency by electroporation in vivo", JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 83, no. 1-2, 29 September 2000 (2000-09-29), pages 147 - 152, XP004212162, ISSN: 0168-1656 *

Also Published As

Publication number Publication date
WO2001068889A2 (en) 2001-09-20
AU2001250859A1 (en) 2001-09-24

Similar Documents

Publication Publication Date Title
Langevin et al. Mechanical signaling through connective tissue: a mechanism for the therapeutic effect of acupuncture
Cabelguen et al. Bimodal locomotion elicited by electrical stimulation of the midbrain in the salamander Notophthalmus viridescens
EP0472712A4 (en) Novel sequences preferentially expressed in early seed development and methods related thereto
ATE185083T1 (en) DEVICE FOR ADMINISTRATION OF MEDICATIONS AND GENES BY ELECTROPORATION
WO1995027044A1 (en) ALPHAVIRUS cDNA VECTORS
IL134842A0 (en) Method of delivering genes to antigen presenting cells of the skin
ATE235558T1 (en) TRANSFORMATION OF ANIMAL SOMATIC CELLS USING PARTICLES
NZ514228A (en) Method of Expressing Antigens on the Surface of Antigen Presenting Cells by Photochemical Internalisation
NO960309L (en) Agonists and antagonists of human interleukin-10
WO2001068889A3 (en) Method for gene transfection and vaccination through skin using electropermeabilization
PT1699480E (en) Allogeneic tumor therapeutic agent
WO2001068828A3 (en) Compositions and methods for regulated protein expression in gut
AU2003246537A1 (en) Device for needle-free injection of a medium into the tissue of a human or an animal, device for needle free production of an injection channel and method for the needle free injection of a medium in the tissue
KR102628416B1 (en) stimulate hair growth
KR101713061B1 (en) Strengthener Of Muscle Around Mouth
AU4037299A (en) Genetically-modified fibroblasts and the use thereof
DE69939212D1 (en) POLYPEPTIDE WITH ACTIVITY AGAINST THE HUMAN IMMUNEFICIENCY VIRUS, ENCODING GENES AND PROCESS FOR PREPARING THE POLYPEPTIDE
US20110123970A1 (en) Taxidermy flesh removal system and method
JPWO2006120767A1 (en) Spa device for hand treatment and spa method for hand treatment
EP1151756A4 (en) Application of polyacrylamide gel for forming a capsule in the tissue of a mammal organism, method for cultivating cells and method for therapy of oncological diseases and the diabetes mellitus
WO2002068629A3 (en) Dna constructs for cytoplasmic and mithochondrial expression and methods of making and using same
WO1999045116A3 (en) Human homolog of a nuclear migration gene and its use
CN1293038A (en) Composition for preparing medicines, beautifying and cosmetics and its application
HK1044568A1 (en) Stress-responsive induction of a therapeutic agent and methods of use
WO2004083364A3 (en) Cell preparation and use of the preparation for treating joints and cartilage defects, and methods for the production thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP